Gabriele Bergers Lab

Research focus

​The long-term goal of our lab is to conduct a comprehensive investigation that defines the dialogues of heterogeneous tumor cell subtypes, and the vasculature and immune cells in the distinct tumor vascular niches in response to standard as well as targeted therapies including antiangiogenic and immune-modulating therapies. The results forthcoming, will enable us to identify suitable polytherapies that are adapted to the heterogeneous cancer responses to more successfully impede therapeutic resistance and prolong survival.

Cancers are heterogeneous entities in which tumor cell populations as well as distinct host cell constituents form a dynamic and interactive tumor community that is pivotal not only for the genesis and progression of a tumor but also for the tumor’s ability to resist therapeutic elimination. Extensive characterization of the genome, epigenome and transcriptome of tumor cells has provided a higher-resolution picture of their alterations revealing substantial inter- and intra-tumor heterogeneity. A further layer of complexity arises from the different normal host cell constituents within the tumor that comprise the tumor microenvironment.  They are composed of a wide variety of non-neoplastic stromal cells, of which the vasculature with its endothelial cells and pericytes, and the various infiltrating and resident immune cells are dominant inhabitants in all tumors while the type and abundance of other cell types can be more tissue-specific. 

Importantly, tumor cells and host cell constituents can form microanatomical compartments within the tumor to regulate metabolic needs, immune surveillance, survival, invasion, metastasis and cancer stem cell (CSC) maintenance. These microenvironmental niches exhibit communication centers in which tumor and host cell populations dynamically interact via direct cell contact or paracrine signaling cues to ensure maintenance, growth and protection of tumor cells and CSC from immune surveillance and therapeutic threats. Although tumor niches have been portrayed as conceptually similar in a variety of tumor types, there exist distinct specialized tumor niches of which the vasculature is an integral regulatory part. Taking advantage of various transgenic and orthotopic mouse models of tumorigenesis and human tumor tissue samples, we have predominantly been studying vascular niches in glioblastoma (GBM), pancreatic neuroendocrine tumors (PNET) and breast cancer. Thereby, our lab has identified several mechanisms of resistance to antiangiogenic therapy that are either driven by tumor cells or immune cells.

Current topics

  • Understanding mechanistic underpinnings of tumor-microenvironment-governed resistance with a focus on tumor cell heterogeneity.
  • Tumor vascular modulation to enhance therapeutic efficacy.
  • Explore new avenues to create enduring immune-stimulating effects in primary tumors and metastatic lesions.


Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formationAllen E* Jabouille A* Rivera L Lodewijckx I Missiaen R Steri V Feyen K Tawney J Hanahan D Michael I Bergers GScience Translational Medicine, 9, eaak9679, 2017* or °: authors contributed equally
Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapyRivera L. B Meyronet D Hervieu V Frederick M. J Bergsland E Bergers G.Cell Reports, 11, 577-91, 2015
Glioblastoma: Defining Tumor NichesHambardzumyan D Bergers G.TRENDS CANCER, 1, 252-265, 2015
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complexLu K Chang J. H Parachoniak C. A Pandika M. M Aghi M. K Meyronet D Isachenko N Fouse S. D Phillips J Cheresh D. A Park M Bergers G.CANCER CELL, 22, 21-35, 2012
Modes of resistance to anti-angiogenic therapyBergers G. Hanahan DNATURE REVIEWS CANCER, 8, 592-603, 2008

Job openings


Why VIB Cores are nicknamed 'technology centers of excellence'

20/03/2019 - In this edition of VIB Times, you will explore the broad offer of VIB cores, which reach far beyond simply providing technological support. You’ll also gain insight into their histories and discover the newest de-risked technologies they make available.

ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB

01/09/2017 - ​ONCURIOUS NV, a biotech company focusing on the development of innovative oncology treatments, announces that it has reached principle agreement with VIB to acquire exclusive licences to a portfolio of five unique next generation immuno-oncology assets.

Specialized blood vessels enhance tumor-fighting immunotherapy

12/04/2017 - Scientists from VIB and KU Leuven, together with colleagues from the University of California and the Swiss Institute for Experimental Cancer Research have demonstrated that , anti-angiogenic therapy can improve immune boosting treatments.

Gabriele Bergers

Gabriele Bergers

Research area(s)

Model organism(s)


PhD: Univ. of Vienna and IMP, Austria, 1993
Research Scientist: Univ. of California, San Francisco, USA, 1994-01
Assistant/Associate Professor: Univ. of California, San Francisco, USA, 2001-05/2005-10
Professor: Univ. of California, San Francisco, USA, 2010-16
Adjunct Professor: Univ. of California, San Francisco, USA, 2016-present
VIB Group leader since August 2016

Contact Info

VIB-KU Leuven Center for Cancer BiologyO&N 4, 9e verdCampus GasthuisbergHerestraat 49, bus 912 3000 LEUVENRoute description